{"id":"intravenous-rhpro-uk","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding/hemorrhage"},{"rate":null,"effect":"Intracranial hemorrhage"},{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"rhPro-UK is a serine protease that activates the fibrinolytic cascade by converting inactive plasminogen into active plasmin, which degrades fibrin in thrombi. This mechanism enables clot dissolution in acute thrombotic conditions. The drug is administered intravenously to achieve systemic thrombolysis.","oneSentence":"Recombinant human prourokinase (rhPro-UK) is a thrombolytic agent that converts plasminogen to plasmin, dissolving blood clots.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:52.110Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"},{"name":"Acute myocardial infarction"},{"name":"Pulmonary embolism"}]},"trialDetails":[{"nctId":"NCT07389460","phase":"PHASE3","title":"Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND)","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2026-01-31","conditions":"Acute Ischemic Stroke","enrollment":820},{"nctId":"NCT06115070","phase":"PHASE4","title":"Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-01","conditions":"Thrombosis, Acute Ischemic Stroke (AIS)","enrollment":390},{"nctId":"NCT06841965","phase":"PHASE3","title":"Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-01","conditions":"Stroke, Acute Ischemic Stroke","enrollment":280},{"nctId":"NCT06749834","phase":"PHASE3","title":"Intravenous Thrombolysis and NOAC","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-01-27","conditions":"Acute Ischemic Stroke","enrollment":280},{"nctId":"NCT06841978","phase":"PHASE3","title":"Intravenous Thrombosis and Patients with Prior Ischemic Stroke Within 3 Months","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-01","conditions":"Stroke, Acute Ischemic Stroke","enrollment":306},{"nctId":"NCT05507645","phase":"PHASE3","title":"ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE)","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2022-11-15","conditions":"Ischemic Stroke, Mild, Thrombosis","enrollment":1446},{"nctId":"NCT03108833","phase":"PHASE2","title":"A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism","status":"COMPLETED","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2017-06-06","conditions":"Acute Pulmonary Embolism","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Intravenous PUK","Intravenous recombinant human prourokinase"],"phase":"phase_3","status":"active","brandName":"Intravenous rhPro-UK","genericName":"Intravenous rhPro-UK","companyName":"First Affiliated Hospital Xi'an Jiaotong University","companyId":"first-affiliated-hospital-xi-an-jiaotong-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recombinant human prourokinase (rhPro-UK) is a thrombolytic agent that converts plasminogen to plasmin, dissolving blood clots. Used for Acute ischemic stroke, Acute myocardial infarction, Pulmonary embolism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}